drug
lactitol
Marketedupdated 3mo agoby Sebela Pharmaceuticals Inc
Approvedcommunity read0 votes
all catalysts(0)
nothing on the calendar yet
Trials studying lactitol
- phase3VAL-083 Phase 3 Study in Temozolomide-Avastin (Bevacizumab) Recurrent GBM
- phase2Safety Study of VAL-083 and Radiotherapy in Patients With Newly Diagnosed GBM Having Unmethylated MGMT Expression
- phase2Study of VAL-083 in Patients With MGMT Unmethylated, Bevacizumab-naive Glioblastoma in the Adjuvant or Recurrent Setting
- phase2Safety Study of VAL-083 in Patients With Recurrent Malignant Glioma
Patent cliff
source: FDA Orange Bookfirst barrier falls
May 12, 2037
~10.7 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (1)
- May 12, 2037method-of-use (U-1516)US 10806743
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 24m ago
Found something off?
comments(0)
5-min edit window · permanent after that